natgillin/translations-raw huggingface dataset:
and R2 are independently selected from hydrogen, hydroxyl, -(C1-C3)alkyl, branched-(C3-C6)alkyl and -(C3-C6)cycloalkyl or R1 and R2 together with the carbon to which they are attached, forms a -(C3-C6)cycloalkyl ring in a spiro manner; 
i R2 su neovisno odabrani od vodika, hidroksila, -(C1-C3)alkila, granatog-(C3-C6)alkila i -(C3-C6)cikloalkila ili R1 i R2 zajedno sa ugljikom za koji su vezani, formiraju -(C3-C6)cikloalkil prsten na spiro način;
or when Y is C(Z'), Z and Z' together forms a 5 or 6 membered aromatic ring system having 1 to 3 heteroatoms independently selected from S(O)n or N and the said ring is optionally substituted by 1-2 substituents independently selected from R8; 
ili kada je Y jednako C(Z’), Z i Z’ zajedno formiraju 5 ili 6 –člani aromatični sustav prstena koji ima 1 do 3 heteroatoma neovisno odabranih od S(O)n ili N i navedeni prsten je izborno supstituiran sa 1-2 supstituenata neovisno odabranih od R8;
and R2 are independently selected from hydrogen and hydroxyl; 
i R2 su neovisno odabrani od vodika i hidroksila;
is independently selected from hydrogen and glucuronate; 
je neovisno odabran od vodika i glukuronata;
and R6 is independently selected from hydrogen, -(C1-C6)alkyl and -COR7 or R5 and R6 are taken together with nitrogen to form a 3 to 8 membered monocyclic heterocycle ring, wherein the said monocyclic ring contain 0, 1, 2 or 3 ring heteroatoms selected from O or N; 
i R6 je neovisno odabran od vodika, -(C1-C6)alkila i -COR7 ili R5 i R6 su uzeti zajedno sa azotom tako da formiraju 3 do 8 –člani monociklični heterociklični prsten, pri čemu navedeni monociklični prsten sadrži 0, 1, 2 ili 3 heteroatoma u prstenu odabrana od O ili N;
is independently selected from hydrogen, -(C3-C6)cycloalkyl, aryl, heteroaryl,-CF3, -CO2R7 and -NR5R6, wherein the said aryl or heteroaryl may be further substituted with 1-3 substituents selected from R9. 
je neovisno odabran od vodika, -(C3-C6)cikloalkila, arila, heteroarila, -CF3, -CO2R7 i -NR5R6, pri čemu navedeni aril ili heteroaril može biti dalje supstituiran s 1-3 supstituenta odabrana od R9;
The compound as claimed in claim 1, which is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, koji je odabran iz grupe koja se sastoji od:
An abuse deterrent or misuse deterrent transdermal patch system comprising a patch backing layer, wherein said backing layer comprises a distal side and a proximal side, wherein one or more aversive agents is incorporated into or irreversibly adhered onto the distal side of the backing layer, wherein an adhesive layer is adhered to the proximal side of the backing layer and wherein the one or more aversive agents exhibits a biphasic release profile when immersed in a dissolution medium. 
Transdermalni sustav flastera sa onemogućenom zloupotrebom ili onemogućenom pogrešnom upotrebom koji sadrži potporni sloj flastera, gdje spomenuti potporni sloj ima distalnu stranu i proksimalnu stranu, gdje jedno ili više odbojnih sredstava je ugrađeno u ili ireverzibilno prilijepljeno na distalnu stranu potpornog sloja, gdje je ljepljivi sloj prilijepljen na proksimalnu stranu potpornog sloja i gdje jedno ili više odbojnih sredstava pokazuje bifazni profil oslobađanja kada se uroni u medij za rastvaranje.
the transdermal patch system and the adhesive layer is free or essentially free of any drug; or 
transdermalni sustav flastera i ljepljivi sloj je bez ili suštinski bez bilo kojeg lijeka; ili
the adhesive layer is a therapeutically active agent-containing adhesive layer. 
ljepljivi sloj je ljepljivi sloj koji sadrži terapeutski aktivno sredstvo.
The system of claim 2 or 3, wherein the system further comprises a release liner. 
Sustav prema zahtjevu 2 ili 3, gdje sustav dalje obuhvaća zaštitnu foliju.
The system of claim 4, wherein the release liner is a permeable release liner, preferably a perforated permeable release liner. 
Sustav prema zahtjevu 4, gdje je zaštitni sloj propusni zaštitni sloj, poželjno perforirani propusni zaštitni sloj.
The system of claim 5, wherein the perforated permeable release liner comprises holes from 0.05 to 0.50 mm in diameter, optionally wherein the holes are at a density of from 75 to 150 holes per square centimeter. 
Sustav prema zahtjevu 5, gdje perforirani propusni zaštitni sloj sadrži rupe od 0.05 do 0.50 mm u promjeru, opcionalno gdje su rupe gustoće od 75 do 150 rupa po kvadratnom centimetru.
The system of any of claims 8 to 11, wherein the one or more aversive agents is incorporated into a polymer layer, optionally wherein the polymer layer comprises one or more polymers selected from the group consisting of polyisobutylene, styrene-isoprene-styrene copolymer, natural rubber, ethylene/vinyl acetate copolymers, polyvinyl pyrrolidone, cross-linked polyvinyl pyrrolidone and cellulosic polymers, wherein the polymer is preferably polyisobutylene. 
Sustav prema bilo kojem od zahtjeva 8 do 11, gdje je jedno ili više odbojnih sredstava uključeno u polimerni sloj, opcionalno gdje polimerni sloj sadrži jedan ili više polimera izabranih iz grupe koju čine poliizobutilen, stiren-izopren-stiren kopolimer, prirodna guma, etilen/vinil acetatni kopolimeri, polivinil pirolidon, umreženi polivinil pirolidon i celulozni polimeri, gdje je polimer poželjno poliizobutilen.
The system of claim 8, wherein the therapeutically active agent is selected from the group consisting of sex steroid hormones, non-steroidal anti-inflammatory agents, glucocorticoids, opioids, opiate analgesics, and stimulants, preferably selected from an opioid, an opiate analgesic and a stimulant, more preferably selected from fentanyl, sufentantil, buprenorphine and methylphenidate. 
Sustav prema zahtjevu 8, gdje je terapeutski aktivno sredstvo izabrano iz grupe koju čine seksualni steroidni hormoni, nesteroidna antiinflamatorna sredstva, glukokortikoidi, opioidi, opijatni analgetici i stimulanti, poželjno izabrani između fentanila, sufentantila, buprenorfina i metilfenidata.
The system of claim 8, wherein the permeable release liner is a perforated permeable release liner, optionally wherein the perforated permeable release liner comprises holes from 0.05 to 0.50 mm in diameter. 
Sustav prema zahtjevu 8, gdje je propusni zaštitni sloj perforirani propusni zaštitni sloj, opcionalno gdje perforirani propusni zaštitni sloj sadrži rupe od 0.05 do 0.50 mm u promjeru.
The system of claim 10, wherein the holes are at a density of from 75 to 150 holes per square centimeter. 
Sustav prema zahtjevu 10, gdje su rupe gustoće od 75 do 150 rupa po kvadratnom centimetru.
An antibody that specifically binds to an epitope within residues 118-126 of human alpha-synuclein, residues being numbered according to SEQ ID NO: 1, for use in prophylaxis or treatment of a Lewy body disease (LBD) selected from Parkinson's disease, including idiopathic Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBVAD), pure autonomic failure, Lewy body dysphagia, incidental LBD, inherited LBD, multiple system atrophy, olivopontocerebellar atrophy, striatonigral degeneration and Shy-Drager syndrome, wherein the antibody competes with monoclonal antibody 9E4 for binding to human alpha-synuclein, wherein antibody 9E4 is produced by hybridoma JH17.9E4.3.37:1.14.2 deposited as ATCC accession number PTA-8221. 
Antitijelo koje se specifično veže za epitop unutar ostataka 118-126 humanog alfa-sinukleina, pri čemu su ostaci obilježeni prema SEQ ID NO: 1, za upotrebu u profilaksi ili liječenju bolesti Lewyjevog tijela (LBD) koja je izabrana od Parkinsonove bolesti, uključujući idiopatsku Parkinsonovu bolest, demenciju sa Lewyjevim tijelima (DLB), bolest difuznih Lewyjevih tijela (DLBD), varijantu Alzheimerove bolesti sa Lewyjevim tijelom (LBVAD), sindrom čiste autonomne disfunkcije, disfagiju Lewyjevih tijela, slučajnu LBD, nasljeđenu LBD, višestruku atrofiju sistema, olivopontocerebelarnu atrofiju, striatonigralnu degeneraciju i Shy-Dragerov sindrom, gde se antitijelo natječe s monoklonskim antitijelom 9E4 za vezivanje za humani alfa-sinuklein, pri čemu se antitijelo 9E4 proizvodi od hibridoma JH17.9E4.3.37:1.14.2 deponiranog pod ATCC pristupnim brojem PTA-8221.
The antibody for use according to claim 1, wherein the disease is Parkinson's disease. 
Antitijelo za upotrebu prema zahtjevu 1, pri čemu je bolest Parkinsonova bolest.
The antibody for use according to any preceding claim, wherein the antibody is administered intraperitoneally, orally, subcutaneously, intracranially, intramuscularly, topically, intranasally or intravenously. 
Antitijelo za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu se antitijelo primjenjuje intraperitonealno, oralno, subkutano, intrakranijalno, intramuskularno, topikalno, intranazalno ili intravenozno.
the antibody binds to membrane bound alpha synuclein from the exterior of the cell and a complex of antibody and alpha synuclein are endocytosed into the cell and combine with a lysosome within the cell, or 
antitijelo veže za membranski vezani alfa sinuklein sa vanjskog dijela stanice i kompleks antitijela i alfa sinuklelina se endocitozom unosi u stanicu i kombinira se sa lizozomom unutar stanice, ili
the antibody and alpha synuclein are separately endocytosed and combined with a lysosome within the cell. 
antitijelo i alfa sinuklein se odvojeno unose endocitozom i kombiniraju se sa lizozomom unutar stanice.
Use of an antibody as defined in any preceding claim in the manufacture of a medicament for prophylaxis or treatment of a Lewy body disease (LBD) selected from Parkinson's disease, including idiopathic Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBVAD), pure autonomic failure, Lewy body dysphagia, incidental LBD, inherited LBD, multiple system atrophy, olivopontocerebellar atrophy, striatonigral degeneration and Shy-Drager syndrome. 
Upotreba antitijela kao što je definirano u bilo kojem prethodnom zahtjevu za dobivanje lijeka za profilaksu ili liječenje bolesti Lewyjevog tijela (LBD) koja je izabrana od Parkinsonove bolesti, uključujući idiopatsku Parkinsonovu bolest, demenciju sa Lewyjevim tijelima (DLB), bolest difuznih Lewyjevih tijela (DLBD), varijantu Alzheimerove bolesti sa Lewyjevim tijelom (LBVAD), sindrom čiste autonomne disfunkcije, disfagiju Lewyjevih tela, slučajnu LBD, naslijeđenu LBD, višestruku atrofiju sistema, olivopontocerebelarnu atrofiju, striatonigralnu degeneraciju i Shy-Dragerov sindrom.
The composition for use according to claim 1 or 2, wherein a therapeutically effective amount of the composition is to be administered prior to, concurrent to, or subsequent to other active agent(s) for treating Parkinsonian Syndromes and/or side effects of said active agent(s). 
Pripravak za uporabu sukladno zahtjevu 1 ili 2, naznačen time, da je terapeutski učinkovita količina pripravka primjenjivati prije, istodobno ili nakon drugog aktivnog sredstva (a) za liječenje bolesti s Parkinsonovim sindromima i / ili nuspojave navedenog aktivnog sredstva (sredstava).
The composition for use according to any one of claims 1 to 3, wherein said neurodegenerative disease with Parkinsonian Syndromes is Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration or Lewy body dementia. 
Pripravak za uporabu sukladno bilo kojem od zahtjeva 1 do 3, naznačen time, da spomenuta neurodegenerativna bolest sadrži Parkinsonove sindrome su Parkinsonova bolest, progresivna supranuklearna paraliza, višestruka atrofija sustava, kortikobazalni degeneracija ili demencija Lewyjevog tijela.
The salt according to claim 1, wherein the amine is selected from the group consisting of ammonia, a primary amine, a secondary amine, a tertiary amine, a quaternary ammonium compound, an amino alcohol, an amino sugar and an amino acid; preferably wherein the amine is selected from the group consisting of an amino alcohol, an amino sugar and an amino acid. 
Sol sukladno zahtjevu 1, naznačena time što je amin odabran iz grupe koja se sastoji od amonijaka, primarnog amina, sekundarnog amina, tercijarnog amina, kvaternog amonijevog spoja, amino alkohola, amino šećera i aminokiselina; pri čemu je amin posebice odabran iz grupe koja se sastoji od amino alkohola, amino šećera i aminokiseline..
The salt according to claim 1 selected from the group consisting of ammonium, benzathine, trimethylglycine (betaine), ethanolamine, diethanolamine, diethylamine, arginine, lysine, choline, deanol, 2-diethylaminoethanol, N-methylglucamine (meglumine), N-ethylglucamine (eglumine) and tromethamine salts. 
Sol sukladno zahtjevu 1 odabrana iz grupe koja se sastoji od amonijeve, benzatin, trimetilglicin (betain), etanolamin, dietanolamin, dietilamin, arginin, lizin, kolin, deanol, 2-dietilaminoetanol, N-metilglukamin (meglumin), N-etilglukamin (eglumin) i trometaminske soli.
The salt of according to claim 1, which is selected from the group consisting of: 
Sol sukladno zahtjevu 1, naznačena time što je odabrana iz grupe koja se sastoji od:
The salt according to any one of claims 1 to 4, which is in a crystalline form. 
Sol sukladno bilo kojem od zahtjeva 1 do 4, naznačena time što je u kristaliziranom obliku.
The salt according to any one of claims 1 to 4, which is in an amorphous form. 
Sol sukladno bilo kojem od zahtjeva 1 do 4, naznačena time što je u amorfnom obliku.
optionally heating the mixture to a temperature at or below the solvent boiling point; 
opcionalno zagrijavanje mješavine na temperature na ili ispod točke vrenja otapala;
optionally cooling the mixture; and 
opcionalno hlađenje mješavine; i
The method according to claim 8, wherein the anti-solvent is acetone or ethyl acetate. 
Postupak sukladno zahtjevu 8, naznačen time što je anti-otapalo aceton ili etil acetat.
The method according to claim 7 or 8, wherein the amine is selected from the group consisting of ammonia, a primary amine, a secondary amine, a tertiary amine, a quaternary ammonium compound, an amino alcohol, an amino sugar and an amino acid. 
Postupak sukladno zahtjevu 7 ili 8, naznačen time što je amin odabran iz skupine koja se sastoji od amonijaka, primarnog amina, sekundarnog amina, tercijarnog amina, kvaternog amonijevog spoja, amino alkohola, amino šećera i aminokiseline.
A pharmaceutical composition comprising a therapeutically effective amount of a salt according to any one of claims 1 to 6 and optionally at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient, preferably wherein the composition is in a form selected from the group consisting of tablets, pills, capsules, pellets, granules, powders, lozenges, sachets, cachets, patches, elixirs, suspensions, dispersions, emulsions, solutions, syrups, aerosols, ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders, 
Farmaceutski pripravak, naznačen timešto sadrži terapeutski učinkovitu količinu soli prema bilo kojem od zahtjeva 1 do 6 i izborno najmanje jedan farmaceutski prihvatljiv nosač, razrjeđivač, vehikulum ili ekscipijent, poželjno gdje je sastav u obliku odabranom iz grupe koja se sastoji od tableta, pilula, kapsula, peleta, granula, prašaka, pastila, vrećica, paketića, flastera, eliksira, suspenzija, disperzija, emulzija, otopina, sirupa, aerosola, masti, mekih i tvrdih želatinskih kapsula, supozitorija, sterilnih injekcijskih otopina, i sterilnih zapakiranih prašaka, poželjnije gdje je pripravak pogodan za primjenu oralnim, transdermalnim ili topikalnim putem.
The pharmaceutical composition of claim 12 for use in: 
Farmaceutski sastav prema zahtjevu 12, naznačen time, da se koristi u:
The pharmaceutical composition for use of claim 13, wherein the disease or disorder associated with altered glucose metabolism is selected from the group consisting of hyperglycemia, diabetes, insulin resistance and obesity. 
Farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time, da je bolest ili poremećaj povezan s izmijenjenim metabolizmom glukoze odabran iz skupine koja se sastoji od hiperglikemije, dijabetesa, inzulinske rezistencije i pretilosti.
The pharmaceutical composition for use of claim 13, wherein the brain disease characterized by amyloid plaque deposits is Alzheimer's disease. 
Farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time da je bolest mozga naznačena amiloidnim naslagama plaka Alzheimerova bolest.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease or one or more symptoms associated with a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease is chosen from Alzheimer's disease, ALS, MSA-P, MSA-C, frontotemporal dementia with parkinsonism, progressive supranuclear palsy, corticobasal degeneration, cerebellar downbeat nystagmus, Lewy Body dementia, and ataxia telangiectasia (Louis Barr disease), and wherein acetyl-leucine, or a pharmaceutically acceptable salt thereof is administered at least two times a day to achieve a total daily dose of from about 0.5 g to about 15 g. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju neurodegenerativne bolesti ili jednog ili više simptoma povezanih s neurodegenerativnom bolešću kod subjekta kojem je to potrebno, pri čemu je neurodegenerativna bolest izabrana od Alzheimerove bolesti, ALS, MSA-P, MSA-C, frontotemporalne demencije s parkinsonizmom, progresivne supranuklearne paralize, kortikobazalne degeneracije, cerebelarnog smanjenog nistagmusa, demencije Lewyjevih tjelešaca, i ataksije teleangiektazije (Louis Barrova bolest), te pri čemu se acetil-leucin, ili njegova farmaceutski prihvatljiva sol primjenjuje najmanje dva puta dnevno da bi se postigla ukupna dnevna doza od oko 0,5 g do oko 15 g.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 to improve in a subject in need thereof a biochemical marker of a neurodegenerative disease over time, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, za poboljšanje kod subjekta kojem je to potrebno biokemijskog markera neurodegenerativne bolesti tijekom vremena, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-4, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-6, wherein the use comprises administering the acetyl-leucine to the subject in need thereof at a therapeutically effect amount of from about 1 g to about 15 g per day, from about 1 g to about 10 g per day, from about 1.5 g to about 7 g per day, from about 4 g to about 6 g per day, or from about 4 g to about 5 g per day. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što uporaba obuhvaća davanje acetil-leucina subjektu kojemu je to potrebno u terapeutski učinkovitoj količini od oko 0,5 g do oko 15 g dnevno, od oko 1 g do oko 10 g dnevno, od oko 1,5 g do oko 7 g dnevno, od oko 4 g do oko 6 g dnevno, ili od oko 4 g do oko 5 g dnevno.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 to provide neuroprotection in a subject having, suspected of having, or at risk of having a neurodegenerative disease, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, kako bi se osigurala neuroprotekcija kod subjekta koji ima, za kojeg se sumnja da ima ili ima rizik od neurodegenerativne bolesti, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease or one or more symptoms associated with a neurodegenerative disease in a subject in need thereof, for use in delaying progression of a neurodegenerative disease or one or more symptoms associated with a neurodegenerative disease over time as compared to typical disease progression, for use in reversing progression of a neurodegenerative disease or one or more symptoms associated with a neurodegenerative disease over time, or for use in improving in a subject in need thereof a biochemical marker of a neurodegenerative disease over time, wherein the usemethod comprises administering a therapeutically effective amount of the acetyl-leucine to the subject for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina. Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, za odgađanje napredovanja neurodegenerativne bolesti ili jednog ili više simptoma povezanih s neurodegenerativnom bolešću tijekom vremena u usporedbi s tipičnim napredovanjem bolesti, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.